SK283206B6 - Inhibítory agregácie krvných doštičiek, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie - Google Patents

Inhibítory agregácie krvných doštičiek, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie Download PDF

Info

Publication number
SK283206B6
SK283206B6 SK23-98A SK2398A SK283206B6 SK 283206 B6 SK283206 B6 SK 283206B6 SK 2398 A SK2398 A SK 2398A SK 283206 B6 SK283206 B6 SK 283206B6
Authority
SK
Slovakia
Prior art keywords
formula
compound
triazolo
pyrimidin
propylthio
Prior art date
Application number
SK23-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK2398A3 (en
Inventor
David Cox
Anthony Ingall
Paul Willis
Original Assignee
Astra Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9514074.5A external-priority patent/GB9514074D0/en
Priority claimed from GBGB9520311.3A external-priority patent/GB9520311D0/en
Priority claimed from GBGB9522837.5A external-priority patent/GB9522837D0/en
Application filed by Astra Pharmaceuticals Ltd. filed Critical Astra Pharmaceuticals Ltd.
Publication of SK2398A3 publication Critical patent/SK2398A3/sk
Publication of SK283206B6 publication Critical patent/SK283206B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK23-98A 1995-07-11 1996-07-04 Inhibítory agregácie krvných doštičiek, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie SK283206B6 (sk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9514074.5A GB9514074D0 (en) 1995-07-11 1995-07-11 Compounds
GBGB9520311.3A GB9520311D0 (en) 1995-10-05 1995-10-05 Compounds
GBGB9522837.5A GB9522837D0 (en) 1995-11-08 1995-11-08 Compounds
PCT/SE1996/000911 WO1997003084A1 (en) 1995-07-11 1996-07-04 New inhibitors of platelet aggregation

Publications (2)

Publication Number Publication Date
SK2398A3 SK2398A3 (en) 1999-01-11
SK283206B6 true SK283206B6 (sk) 2003-03-04

Family

ID=27267806

Family Applications (1)

Application Number Title Priority Date Filing Date
SK23-98A SK283206B6 (sk) 1995-07-11 1996-07-04 Inhibítory agregácie krvných doštičiek, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie

Country Status (25)

Country Link
US (1) US5747496A (no)
EP (1) EP0840740B1 (no)
JP (1) JP4084415B2 (no)
KR (1) KR100444123B1 (no)
CN (1) CN1069321C (no)
AR (1) AR003453A1 (no)
AT (1) ATE217010T1 (no)
AU (1) AU699034B2 (no)
BR (1) BR9609467A (no)
CA (1) CA2226758A1 (no)
CZ (1) CZ297200B6 (no)
DE (1) DE69621021T2 (no)
EE (1) EE03616B1 (no)
HU (1) HU221880B1 (no)
IL (1) IL122814A (no)
IS (1) IS1790B (no)
MY (1) MY116542A (no)
NO (1) NO310624B1 (no)
NZ (1) NZ312258A (no)
PL (1) PL182680B1 (no)
SA (1) SA96170272B1 (no)
SK (1) SK283206B6 (no)
TR (1) TR199800019T1 (no)
TW (1) TW427996B (no)
WO (1) WO1997003084A1 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946561B1 (en) * 1996-12-20 2002-02-13 AstraZeneca AB Triazolo(4,5-d)pyrimidinyl derivatives and their use as medicaments
SE9702772D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
TW530058B (en) * 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
SE9702774D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702773D0 (sv) * 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
NZ505250A (en) * 1998-02-17 2002-10-25 Astrazeneca Uk Ltd Novel triazolo(4,5-d) pyrimidine compounds and pharmaceuticals thereof.
SE9802574D0 (sv) * 1998-07-17 1998-07-17 Astra Pharma Prod Novel compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6897201B2 (en) * 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
AR039558A1 (es) * 2000-08-21 2005-02-23 Inspire Pharmaceuticals Inc Composiciones y metodo para el tratamiento de glaucoma o hipertension ocular
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US20020169730A1 (en) * 2001-08-29 2002-11-14 Emmanuel Lazaridis Methods for classifying objects and identifying latent classes
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US7674791B2 (en) * 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
US7285550B2 (en) * 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
WO2004092173A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
EP1618108A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005040174A1 (en) * 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Tetrahydro-furo`3,4-d!dioxole compounds and compositions and method for inhibiting platelet aggregation
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
WO2005039590A1 (en) * 2003-10-21 2005-05-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
US8470834B2 (en) * 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2011216991A1 (en) 2010-02-16 2012-08-30 Actavis Group Ptc Ehf Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
RU2014126351A (ru) 2011-11-30 2016-01-27 Актавис Груп Птс Ехф Новая кристаллическая форма тикагрелора и способ ее получения
WO2014083139A1 (en) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
WO2014206187A1 (zh) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 替卡格雷及其中间体的制备方法
JP6145574B2 (ja) * 2013-06-27 2017-06-14 スーヂョウ ミラクファーマ テクノロジ カンパニー リミテッドＳｕｚｈｏｕ Ｍｉｒａｃｐｈａｒｍａ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．，Ｌｔｄ． チカグレロールの調製方法
CN105061431B (zh) * 2015-07-28 2017-03-29 山东百诺医药股份有限公司 6‑n‑（2‑（甲硫基）乙基）‑2‑（（3,3,3‑三氟丙基）硫代）‑9h‑嘌呤及其制备方法和应用
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
CN112915063B (zh) * 2021-01-25 2022-12-20 刘红枚 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
RU2770405C1 (ru) * 2021-07-05 2022-04-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Производные триазола, проявляющие антиагрегационную активность

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
JP2619710B2 (ja) * 1989-02-27 1997-06-11 日本製紙 株式会社 ２′，３′−ジデオキシプリンヌクレオシド類の製造方法
EP0684953A4 (en) * 1993-02-03 1999-12-22 Gensia Inc ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES.
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain

Also Published As

Publication number Publication date
HUP9802448A3 (en) 2000-03-28
MX9800308A (es) 1998-09-30
CZ2598A3 (cs) 1998-08-12
NO980080L (no) 1998-03-06
US5747496A (en) 1998-05-05
HU221880B1 (hu) 2003-02-28
AU6375196A (en) 1997-02-10
PL182680B1 (pl) 2002-02-28
TW427996B (en) 2001-04-01
CN1195353A (zh) 1998-10-07
AU699034B2 (en) 1998-11-19
BR9609467A (pt) 1999-03-02
JPH11508914A (ja) 1999-08-03
NO310624B1 (no) 2001-07-30
PL324396A1 (en) 1998-05-25
NO980080D0 (no) 1998-01-08
CZ297200B6 (cs) 2006-09-13
MY116542A (en) 2004-02-28
IL122814A (en) 2001-04-30
ATE217010T1 (de) 2002-05-15
DE69621021T2 (de) 2002-10-31
SK2398A3 (en) 1999-01-11
NZ312258A (en) 1999-08-30
EP0840740B1 (en) 2002-05-02
HUP9802448A2 (hu) 1999-05-28
EP0840740A1 (en) 1998-05-13
DE69621021D1 (de) 2002-06-06
TR199800019T1 (xx) 1998-05-21
IL122814A0 (en) 1998-08-16
AR003453A1 (es) 1998-08-05
IS4647A (is) 1998-01-08
KR100444123B1 (ko) 2004-10-14
EE9800026A (et) 1998-08-17
IS1790B (is) 2001-11-28
WO1997003084A1 (en) 1997-01-30
CA2226758A1 (en) 1997-01-30
JP4084415B2 (ja) 2008-04-30
CN1069321C (zh) 2001-08-08
EE03616B1 (et) 2002-02-15
KR19990028885A (ko) 1999-04-15
SA96170272B1 (ar) 2006-06-04

Similar Documents

Publication Publication Date Title
SK283206B6 (sk) Inhibítory agregácie krvných doštičiek, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie
FI110687B (fi) Menetelmä valmistaa N-alkyyli-2-substituoituja ATP-analogeja
FI101793B (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 9-purinyylifosfonih appojohdannaisten valmistamiseksi
US20090253648A1 (en) Tricyclic-Nucleoside Compounds for Treating Viral Infections
US6069132A (en) Phosphazole compounds
HUT64769A (en) Antiviral and antitumoric 2'-desoxi-2',2'-difluorine (4-substituted)-pyrimidine-nucleosides and medical preparatives containing it
JPH01500996A (ja) ２―置換―ｅ―縮合―〔１，２，４〕トリアゾロ〔１，５―ｃ〕ピリミジン類及びそれを含有する医薬組成物
WO1992017488A1 (en) Atp analogues
AU8370798A (en) Novel compounds
EP1232156A1 (en) Novel 1,2,3]-triazolo 4,5-d]pyrimidine compounds
HU217870B (hu) 9-Szubsztituált-9-dezaza-guanin-származékok, ezeket tartalmazó gyógyászati készítmények, és eljárás ezek előállítására
WO2001036438A1 (en) Novel ribose compounds
RU2174518C2 (ru) Производные 3-н-1,2,3-триазоло-[4,5-d]пиримидина, фармацевтическая композиция и способ их получения
KR20010042240A (ko) 트리아조로푸린 유도체, 그 유도체를 함유하는 의약조성물, 아데노신 에이3 수용체 친화제 및 천식치료제
MXPA98000308A (en) New plaque aggregation inhibitors
Bhat et al. Synthesis of certain fluorescent tricyclic nucleosides derived from pyrazolo [3, 4-d] pyrimidine nucleosides
Berry et al. Synthesis and Biological Activity of 4-Amino-1-(β-D-ribofuranosyl) imidazo [4, 5-d] pyridazin-7-one
UA64697C2 (en) Platelet aggregation inhibitors
US20230382909A1 (en) Bicyclic compounds
AU648885C (en) ATP analogues